Novel HIV vaccine☆
|AFFILIATION:||Australian National University, Acton, ACT, Australia|
Track: Medical & Biotech
Area: Infectious Disease
Tech Readiness: TRL 4
Tech Brief: This recombinant vaccine optimises anti-viral host responses, both in mucosal tissue and systemically(blood), using a new adjuvant strategy and delivery regimen. Currently in late preclinical trials, the vaccine shows strong potential for treatment and immunization against HIV. The strategy is a platform technology with applications against other intracellular pathogens.
Value Proposition: 1/ Protection of personnel from existing pandemics: HIV and its co-infections are a huge global health challenge. An effective HIV vaccine could not only protect personnel from this infection, but also has potential as a platform technology to be applied to other prevalent global infections such as TB (a parallel TB vaccine program is in development), and other intracellular pathogens. The suitability of our vector/adjuvant system for simultaneous immunisation against multiple antigens makes it feasible to generate multi-pathogen combination vaccines in the future. 2/ Biological defence: The capability to respond to an emerging threat by constructing a vaccine using a tried and tested vector-adjuvant system, together with antigens tailor-made to address the threat, is potentially an important tool in defence against bioterrorism and battlefield use of biological agents. 3/ Contribution to global welfare: an effective HIV vaccine will make a significant contribution to addressing an intractable and damaging infectious diseases. As part of a wider strategy of ethical engagement with civilian populations, investment in vaccine development has significant benefits for community trust, in-theatre political relationships and Army reputation. The broad range of potential medical indications for ANU's vaccine platform is applicable to almost all likely conflict zones.
Org Type: Academic/Gov Lab